Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 2/20 | 0.41 |
| ▸ | ATRIP | Q8WXE1 | 2/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.39 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.39 |
| ▸ | ITK | Q08881 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3789872 | 0.90 | LATS1 (0.45) | ALDH1A1SMN1; SMN2TP53CYP3A4ADORA2B | |
| SCHEMBL3788917 | 0.89 | MELK (0.41) | RPS6KA3ALDH1A1RPS6KA2RPS6KA1DYRK1A | |
| SCHEMBL3063772 | 0.83 | CYP3A4 (0.42) | ATRATRIPRPS6KA3LRRK2PIK3CA | |
| SCHEMBL3786530 | 0.79 | CYP11B1 (0.49) | ALDH1A1HTTSMN1; SMN2CYP3A4ADORA2B | |
| SCHEMBL3796334 | 0.78 | NUDT1 (0.45) | ATRALDH1A1HTTSMN1; SMN2CYP3A4 | |
| SCHEMBL3789467 | 0.78 | CYP3A4 (0.43) | CYP3A4ADORA2BCYP2C19CDC7PIM1 | |
| SCHEMBL3786726 | 0.78 | ADORA2A (0.42) | ALDH1A1HTTSMN1; SMN2TP53CYP3A4 | |
| SCHEMBL3791710 | 0.77 | CYP11B1 (0.44) | ALDH1A1HTTSMN1; SMN2CYP3A4ADORA2B | |
| SCHEMBL3794517 | 0.77 | NPY5R (0.47) | ALDH1A1HTTSMN1; SMN2CYP3A4ADORA2B | |
| SCHEMBL3788904 | 0.77 | ADORA2B (0.45) | RPS6KA3CYP3A4ADORA2BCYP2C19CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855202-B2 | Imidazopyridine derivatives as A2B adenosine receptor antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-12-21 | — | — | US | claimed |
| US-20080275038-A1 | Imidazopyridine Derivatives as A2b Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-11-06 | — | — | US | claimed |
| US-7855202-B2 | Imidazopyridine derivatives as A2B adenosine receptor antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-12-21 | — | — | US | disclosed |
| US-7855202-B2 | Imidazopyridine derivatives as A2B adenosine receptor antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-12-21 | — | — | US | disclosed |
| US-7855202-B2 | Imidazopyridine derivatives as A2B adenosine receptor antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2010-12-21 | — | — | US | disclosed |
| US-20080275038-A1 | Imidazopyridine Derivatives as A2b Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-11-06 | — | — | US | disclosed |
| US-20080275038-A1 | Imidazopyridine Derivatives as A2b Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-11-06 | — | — | US | disclosed |
| US-20080275038-A1 | Imidazopyridine Derivatives as A2b Adenosine Receptor Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275038-A1 | Imidazopyridine Derivatives as A2b Adenosine Receptor Antagonists | ADORA2B, ADORA2A, ADORA1 | ATR 4169/4885ATRIP 1252/4885RPS6KA3 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.